en · de · es · fr · pt
cjc-1295-notes.peptides6908.com › Blog › Background And Naming Conventions — Reference Sheet

Background And Naming Conventions — Reference Sheet

By Editorial Desk · published 2026-07-09 · last reviewed 2026-08-01 · Blog

somatotroph comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.

Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.

Background and Naming Conventions

The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.

Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.

CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.

Molecular Background and Naming

The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.

CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.

Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.

Cjc-1295 at a glance

PropertyValueNotes
Molecular classSynthetic peptideAnalog of growth hormone-releasing hormone
Chain length29 amino acidsBased on the GRF(1-29) fragment
AppearanceWhite to off-white lyophilized powderCommon research supply form
SolubilitySoluble in water and aqueous buffersPowder requires reconstitution before use
Typical storage−20 °C or belowKept away from light and moisture

Handling Storage and Quality Control

Batch-to-batch consistency depends on solid-phase peptide synthesis and subsequent purification. Coupling efficiency, resin choice, and cleavage conditions all affect the final profile. Counter-ion content and moisture can shift the apparent mass of a batch. Documentation typically includes a certificate of analysis with chromatograms and spectra. Independent verification by a second laboratory is sometimes requested. Whether a given certificate reflects the actual vial contents depends on chain of custody. Analytical methods themselves carry uncertainty that should be stated alongside results.

Lyophilized material is typically stored at minus twenty degrees Celsius or lower. Keeping the vial dry and protected from light preserves peptide integrity. Repeated freeze-thaw cycles can cause aggregation or loss of activity. Once dissolved, solutions are generally kept at two to eight degrees Celsius. Stability data for reconstituted solutions vary, and long-term behavior is not fully established. Working aliquots reduce the number of times a stock container is opened.

Related pages on this site

Background and Receptor Mechanism

Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.

At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.

CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.

Analytical Measurement And Stability

Identity and purity are established with reversed phase high performance liquid chromatography coupled to mass spectrometry. The chromatographic step separates the target peptide from truncated sequences and deletion products, while the mass measurement confirms the expected molecular weight to within a fraction of a dalton. Because the two common variants differ by the presence of the linker, mass alone can distinguish them in the unconjugated state. Amino acid analysis and peptide mapping are used when sequence level confirmation is required.

Lyophilized material is generally stable for extended periods when held at minus twenty degrees Celsius or below and protected from moisture and light. In solution the peptide is more labile; bond hydrolysis, aggregation and oxidation of susceptible residues all proceed faster at ambient temperature. Repeated freeze and thaw cycles should be avoided because they promote clumping and loss of soluble material. The conjugated variant adds a further consideration, since the maleimide group can hydrolyze in aqueous buffer and lose its ability to react with albumin.

Further detail

It remains the deadliest terrorist attack in history, as well as the deadliest incident for firefighters and law enforcement personnel in American history, killing 343 and 72 members, respectively. The crashes of Flight 11 and Flight 175 were the deadliest aviation disasters of all time, and the collision of Flight 77 with the Pentagon resulted in the fourth-highest number of ground fatalities in a plane crash in history. The destruction of the World Trade Center and its environs seriously harmed the U.S. economy and induced global market shocks. Many other countries tightened airport security, strengthened anti-terrorism legislation and expanded their powers of law enforcement and intelligence agencies. The total number of deaths caused by the attacks, combined with the death tolls from the conflicts they directly triggered, has been estimated by the Costs of War Project to be more than 4.5 million. Cleanup of the World Trade Center site (colloquially known as "Ground Zero") was completed in May 2002, while the Pentagon was repaired within a year. After delays in the design of a replacement complex, six new buildings were planned to replace the lost towers at the World Trade Center site, along with a museum and memorial dedicated to those who were killed or injured in the attacks. The tallest building, One World Trade Center, began construction in 2006 and opened in 2014.

The combined revenues of the top 20 fine chemical companies amounted to $10 billion in 2009, representing about 30% of the whole industry. The leading companies are typically divisions of large, diversified chemical companies. In terms of geography, 9 of the top 20 are located in Europe, which is recognized as the cradle of the fine chemical industry. This is the case for the world's #1 company, Lonza, which is headquartered in Basel, Switzerland. Custom manufacturing prevails in northern Europe; the manufacture of active substances for generics, in southern Europe. The second largest geographic area is Asia, housing 7 of the top 20. With 4 large companies, the US ranks last. Whereas the European and U.S. pharma industry constitutes the main customer base for most fine chemical companies, some have a significant share of products and services for the agrochemical industry. Examples are Archimica, CABB, Saltigo (all Germany); DSM, The Netherlands; and Hikal, India. Several large pharmaceutical companies market fine chemicals as subsidiary activity to their production for captive use, including Abbott, USA; Bayer Schering Pharma, Boehringer-Ingelheim, Germany; Daiichi-Sankyo (after the takeover of Ranbaxy), Japan; Johnson & Johnson, USA; Merck KGaA, Germany; and Pfizer (formerly Upjohn), US. Large fine chemical companies, in contrast to mid-sized and small ones, are characterized by:

== Injectable materials == Many different materials have been used as perianal injectable bulking agents. The ideal injectable or implantable material would be biocompatible, non-migratory, non-allergenic, non-carcinogenic and non-immunogenic (and therefore induce a minimal inflammatory and fibrotic reaction). The material should also be easy to inject. The particles should be greater than 80 μm in diameter in order to prevent migration away from the injection site. On the other hand, materials with particles small enough to be used in small caliber needles may be desirable, in order to leave a smaller needle track, which may reduce the chance of leakage of the material via the needle track. Alternatively, some materials are shape-retaining porous hydrogels with no particles. The ideal material should produce an improvement in continence not only in the short term, but in the long term, and repeated procedures should not be necessary. Technically, most materials are particles suspended in a carrier (excipient) solution, which is usually a biodegradable gel. It is not known which of the available materials is the best.

=== Hearing loss === It is not known whether ACE inhibitors or other treatments affect hearing loss. For those with classic Alport syndrome, hearing aids are often required in teenage or young adult years.

=== Mods === Jan. 1997: Dark Night (Quake multiplayer mod) Feb. 1997: Outpost (Quake multiplayer mod) Mar. 1997: Monastery (Quake multiplayer mod) Apr. 1997: SlaughterHouse (Quake multiplayer mod) Jul. 1997: Alba 1 (Quake multiplayer mod) Jul. 1997: Alba 2 (Quake multiplayer mod) Aug. 1997: Starship (Quake multiplayer mod) Nov. 1997: Starship II (Quake multiplayer mod) 1997: Silhouette Of Darkness (Quake multiplayer mod) Special Ops Force: Deathmatch (Quake II multiplayer mod) SlaughterShip (Quake II single player mod) 1999: They Hunger (Half-Life single player mod, later updated and re-released for PC Gamer in Feb. 2000) They Hunger Deathmatch 1-5 (Half-Life multiplayer mods) 2003: Abandoned Factory (Half-Life multiplayer mod)

Sources: en.wikipedia.org

Supporting material

Secukinumab, sold under the brand name Cosentyx among others, is a human IgG1κ monoclonal antibody used for the treatment of psoriasis, ankylosing spondylitis, psoriatic arthritis, and hidradenitis suppurativa. It binds to the protein interleukin (IL)-17A and is marketed by Novartis.

On 11 December, they sent a telegram to People's Liberation Army (PLA) commander Zhu De, backdated to the 9th, officially breaking ties with the Kuomintang and joining the communists under Mao Zedong. This event was known as the Chengdu Uprising.

Skin cancer can be categorized into two groups: melanoma, which is considered more severe, and nonmelanoma skin cancer, which includes basal cell carcinoma and cutaneous squamous cell carcinoma. Mohs micrographic surgery is used for high-risk nonmelanoma skin cancers located in cosmetically critical or sensitive areas like the face, ears, scalp, neck, genitalia, hands, and feet, where tissue conservation is of utmost importance. It is also indicated when the tumor is recurrent, aggressive, large, or painful, which tells us there is invasion of the nerve or vasculature.

==== Inkjet printing ==== Inkjet printing is used for surface filling or image decoration. By utilizing gravity, edible food ink is dropped onto the surface of the food, typically a cookie, cake, or other candy. This is a non-contact method, hence the printhead does not touch the food protecting the food from contamination during image filling. The ink droplets may consist of a broad range of colors allowing users to create unique and individualized food images. An issue with inkjet printing is the food materials being incompatible with the ink resulting in no image or high image distortion. Inkjet printers can be purchased for household or commercial use, and industrial printers are suitable for mass production.

=== Sarcopenia and sarcopenic obesity === In a recently published scoping review led by Kalra, the current evidence linking sarcopenic obesity with cardiovascular disease has been summarised, along with proposed preventive and therapeutic strategies. He has published extensively to enable the diagnosis of sarcopenia and sarcopenic obesity in resource-constrained settings and has led the development of a South Asian consensus document on the subject.

Sources: en.wikipedia.org

Frequently asked questions

Does this compound occur naturally in the body?

No. It is a laboratory-synthesized analog built on a fragment of the natural hormone. The natural peptide is shorter-lived and lacks the stabilizing substitutions found in the synthetic version.

What does the abbreviation DAC refer to?

DAC stands for drug affinity complex, a chemical group that binds the peptide to serum albumin. The binding slows clearance and lengthens the time the molecule stays in plasma compared with the unmodified analog.

Why do different sources report different half-lives for the same name?

Because two distinct molecules are discussed under one informal label. The albumin-binding version clears over several days, while the form without that group clears within roughly half an hour. Mixing results from both creates inconsistent figures.

Is CJC-1295 a natural hormone?

No. It is a synthetic analogue modeled on the first 29 residues of human GHRH. The substitutions and any linker are laboratory modifications rather than features of the endogenous peptide.

Network